



ASISA STANDARD ON DISCLOSURES FOR CRITICAL ILLNESS PRODUCTS

Date first published: 1 September 2009

Last updated: 19 March 2025



1. INTRODUCTION

- 1.1. Critical illness insurance covers a limited number of serious illnesses, such as cancer, a heart attack or a stroke, which could have major impacts on lifestyle, mortality and morbidity.
- 1.2. Critical illness products have become increasingly comprehensive and complex. Insurers also don't provide the same set of critical illness benefits, making like-for-like comparisons very difficult.
- 1.3. Definitions for critical illness cover have to be sufficiently detailed to adequately describe what is covered and what is not to facilitate consistency in claim assessments and decisions. Furthermore, such definitions inevitably require the use of medical terminology. These factors make it difficult for consumers to understand critical illness products. The situation is exacerbated when different insurers use different technical definitions for the same illnesses, making it difficult for consumers to compare products from different insurers.
- 1.4. Standardised critical illness definitions provide greater transparency for consumers to assess and compare different insurance products. It also reduces discrepancies in claim assessments and decisions, for example where one insurer may provide a payout while another rejects a payout.
- 1.5. Against this background, the Standardised Critical Illness Definitions Project “**(SCIDEP)**” was established by ASISA to develop standard definitions for the four “core” diseases which make up more than half of all critical illness claims, namely heart attack, cancer, stroke and coronary artery bypass graft “**(SCIDEP definitions)**”. The SCIDEP committee defined 4 (four) severity levels for each of the 4 (four) core illnesses. This Standard for Disclosures on Critical Illness Products “**(Standard)**” sets out these SCIDEP definitions and severity levels.
- 1.6. This Standard has accordingly been established in the interest of promoting transparency, improve consumer understanding and improving comparability of critical illness products. The Standard aims to ensure consistency in defining critical illnesses in order to provide policyholders with:
 - 1.6.1. the comfort that their claims will be assessed according to industry approved definitions; and
 - 1.6.2. a better understanding of their cover and at what level different insurers will pay out.
- 1.7. The Standard does not attempt to stifle competition as insurers are not restricted in terms of the number of diseases covered, the percentage paid out, the number of payments that can be made, or



the rates that they charge.

- 1.8. This Standard has been developed on the basis of engagements with the Financial Sector Conduct Authority and the National Treasury.
- 1.9. This Standard will be updated from time to time to take account of changes in medical conditions and treatments, as well as global best practice.
- 1.10. This Standard is being shared with ASISA members and the public at large for their consideration and implementation and is binding on ASISA members.

2. SCOPE AND APPLICATION

- 2.1. This Standard applies to all ASISA members that provide critical illness products that cover any of the following 4 (four) core diseases, which make up more than half of critical illness claims:
 - 2.1.1. heart attack;
 - 2.1.2. cancer;
 - 2.1.3. stroke; and
 - 2.1.4. coronary artery bypass graft (“**CABG**”).
- 2.2. This Standard does not require that insurers change their product philosophy or marketing or other product material, save that insurers should use the SCIDEP definitions in their policy contracts and state clearly what percentage they would pay out for the defined illnesses. Hence insurers merely need to map their current pay-outs to the SCIDEP definitions. Changes to the definitions do not need to be applied retrospectively. They only need to be applied to new policies sold after the effective date of the current version of the Standard.

3. GRID

- 3.1. The definitions for each of these illnesses must be read with the criteria for four tiers, A, B, C, and D, with A being the most severe and D being the least severe.
- 3.2. The quotation and contract provided by the insurer must state what percentages the insurer will pay



out for illnesses that meet the SCIDEP definitions at various severity levels in a 4 x 4 grid.

- 3.3. Below is an example of what this grid could look like. It will differ depending on the insurer and the type of critical illness product which is taken out:

Disease	Severity Level			
	A (most severe)	B (moderate impairment)	C (mild impairment)	D (least severe)
Stroke	100%	75%	50%	25%
CABG	100%	75%	50%	25%
Heart attack	100%	75%	50%	25%
Cancer	100%	75%	50%	25%

- 3.4. Although the sixteen definitions (four diseases with four severities) are standardised, the percentage benefit paid for each of the definitions is up to the discretion of each insurer. Therefore, an insurer may pay between 0% and 100% for each severity level of each illness. An insurer may not pay a lower percentage for a higher severity level, although they may pay the same percentage. Examples of possible pay-outs could be:

	Insurer 1	Insurer 2	Insurer 3	Insurer 4	Insurer 5
Severity A	100%	100%	100%	100%	100%
Severity B	75%	0%	100%	100%	100%
Severity C	50%	0%	10%	0%	100%
Severity D	25%	0%	10%	0%	100%

- 3.5. Although it would be ideal for all insurers to use the SCIDEP definitions in their quotations and contracts, there are some practical restrictions that may make this difficult to implement. Hence insurers are required to state that they will honour claims according to the SCIDEP definitions for at least one severity level of each of the four core illnesses that they cover. This means that no insurer may have 0% cover for all four severity levels of any given illness. If a claim is declined on the insurer's

definition, the policyholder will have the right to insist that it is also assessed according to the SCIDEP definitions and severity levels.

4. STROKE

4.1. SCIDEP definition for tiered products

Death of brain tissue due to inadequate blood supply or haemorrhage within the skull resulting in neurological deficit, confirmed by neuro-imaging investigation and appropriate clinical findings by a specialist neurologist. Symptoms and signs, as well as imaging, must confirm a new stroke.

For purposes of the above definition, the following are not covered:

- transient ischaemic attack. This is defined as a transient episode of neurologic dysfunction (irrespective of duration), caused by focal brain, spinal cord, or retinal ischemia, without acute infarction (on neuroimaging investigations);
- vascular disease affecting the eye or optic nerve;
- migraine and vestibular disorders;
- traumatic injury to brain tissue or blood vessels.

Severity levels will be assessed by means of a full neurological examination by a specialist neurologist any time after 3 (three) months.

Level A: Stroke with severe impairment

Needs constant assistance, as measured by:

- the inability to do 3 or more basic activities of daily living (“ADLs”); or
- a whole person impairment (“WPI”*) of greater than 35%.

Level B: Stroke with moderate impairment

Cannot function independently, as measured by:

- the inability to do 6 or more advanced ADLs; or
- a WPI* of 21% to 35%.

Level C: Stroke with mild impairment



Can function independently, but has impairment as measured by:

- the inability to do 3 or more advanced ADLs; or
- a WPI* of 11% to 20%.

Level D: Stroke with almost full recovery

Almost full recovery, with minor residual symptoms or signs, as measured by:

- a permanent objective neurological deficit that is evident on physical examination that has persisted for a continuous period of at least 3 months after the onset of the stroke; or
- a WPI* of 1% to 10%.

** WPI figures are calculated as per the latest American Medical Association Guides to the Evaluation of Permanent Impairment.*

Basic activities of daily living

- **Bathing** – the ability to wash/bathe oneself independently;
- **Transferring** – the ability to move oneself from a bed to a chair or from a bed to a toilet independently;
- **Dressing** – the ability to take off and put on one's clothes independently;
- **Eating** - the ability to feed oneself independently. This does not include the making of food;
- **Toileting** – the ability to use a toilet and cleanse oneself thereafter, independently;
- **Locomotion on a level surface** – the ability to walk on a flat surface, independently;
- **Locomotion on an incline** – the ability to walk up a gentle slope or a flight of steps independently.

Advanced activities of daily living

- **Driving a car** – the ability to open a car door, change gears or use a steering wheel;
- **Medical care** - the ability to prepare and take the correct medication;
- **Money management** – the ability to do one's own banking and to make rational financial decisions;



- **Communicative activities** - the ability to communicate either verbally or in writing;
- **Shopping** - the ability to choose and lift groceries from shelves, as well as carry them in bags;
- **Food preparation** – the ability to prepare food for cooking as well as using kitchen utensils;
- **Housework** – the ability to clean a house or iron clothing;
- **Community ambulation with or without assistive device, but not requiring a mobility device** – the ability to walk around in public places using only a walking stick if necessary;
- **Moderate activities** - activities like moving a table, pushing a vacuum cleaner, bowling, golfing;
- **Vigorous activities** – the ability to partake in running, heavy lifting, sports.

Note: All ADLs will be assessed with the use of assistive devices where appropriate.

4.2. **SCIDEP definition for non-tiered products**

It is recommended that the primary definition of stroke with its exclusions are used for non-tiered products, in combination with any one of the 4 severity levels. The decision on which severity level to use will be a pricing and product philosophy issue.

5. **CABG DEFINITIONS**

5.1. **SCIDEP definition for tiered products**

The undergoing of surgery, regardless of method of surgical access, to correct the narrowing of, or blockage to, one or more coronary artery(ies) by means of a by-pass graft.

For purposes of the above definition, the following is not covered:

Closed coronary artery procedures, including but not limited to coronary angioplasty, stent insertion and all other intra-vascular catheter-based procedures.

Level A

The undergoing of surgery to correct the narrowing of, or blockage to, 3 or more coronary arteries, by means of a by-pass graft.



Level B

The undergoing of surgery to correct the narrowing of, or blockage to, 2 coronary arteries, by means of a by-pass graft.

Level C

The undergoing of surgery to correct the narrowing of, or blockage to, the left main or proximal left anterior descending coronary artery, by means of a by-pass graft.

Level D

The undergoing of surgery to correct the narrowing of, or blockage to, any 1 coronary artery, by means of a by-pass graft.

5.2. **SCIDEP definition for non-tiered products**

Any of the 4 severity level definitions may be used on its own for non-tiered products. The SCIDEP disclosure grid should indicate correctly that severity levels below the chosen definition will have a zero-percentage pay-out.

6. HEART ATTACK DEFINITIONS

6.1. **SCIDEP definition for tiered products**

A heart attack or acute myocardial infarction (“MI”) is defined as acute myocardial injury confirmed by a certified physician as having occurred as a direct consequence of acute myocardial ischemia resulting from inadequate blood supply to the heart.

Not all clinical myocardial infarctions are covered by the SCIDEP definitions set out below. Only the specified severities as set out in level A to D are covered.

Level A: Heart attack with severe permanent impairment in function

A heart attack that meets the criteria as defined under level C, with permanent impairment in one or more of the following functional criteria, as measured 6 weeks post-infarction:

Criterion	Value
NYHA classification	Class 4



METS	1 or less
LVEF	< 30%
LVEDD	> 72
Ultrasound FS in %	< 16%

Notes:

- If more than one functional criterion is impaired, but their values do not conform to one severity level (for example one impaired value is level A and another level B), the final severity level should be determined by giving preference to the more objective criteria, i.e. in the following order:

- 1 LVEF
- 2 LVEDD
- 3 Ultrasound FS
- 4 METS
- 5 NYHA

Level B: Heart attack with mild permanent impairment in function

A heart attack that meets the criteria as defined under level C, with permanent impairment in one or more of the following functional criteria, as measured 6 weeks post-infarction:

Criterion	Value
METS	2 - 7
LVEF	30% - 50%
LVEDD	59 - 72
Ultrasound FS in %	16% - 25%

Notes:

- If more than one functional criterion is impaired, but their values do not conform to one severity level (for example one impaired value is level A and another level B), the final



severity level should be determined by giving preference to the more objective criteria, i.e. in the following order:

- 1 LVEF
- 2 LVEDD
- 3 Ultrasound FS
- 4 METS
- 5 NYHA

Level C: Moderate heart attack of specified severity

This is defined as the death of heart muscle, due to inadequate blood supply, as evidenced by any of the following combinations of criteria:

- 1 Compatible clinical symptoms **AND** raised cardiac biomarkers;
OR
- 2 Compatible clinical symptoms **AND** new pathological Q-waves on ECG as defined in **Annexure A (b)**;
OR
- 3 New pathological Q-waves on ECG as defined in **Annexure A (b)** **AND** raised cardiac biomarkers;
OR
- 4 ST-segment and T-wave changes on ECG indicative of myocardial injury as defined in **Annexure A (a)** **AND** raised cardiac biomarkers.

Where raised cardiac biomarkers are referenced above, they are defined as any one of the following Troponin or Non-Troponin Markers:

Sensitive Troponin Markers

Marker	Value**		
*Assay (test)	Troponin Type	Unit: ng/L	Unit: ng/ml
Roche hsTnT	TnT	> 1000	> 1,0



Abbott ARCHITECT	Tnl	> 3000	> 3,0
Beckman AccuTnl	Tnl	> 5000	> 5,0
Siemens Centaur Ultra	Tnl	> 6000	> 6,0
Siemens Dimension RxL	Tnl	> 6000	> 6,0
Siemens Stratus CS	Tnl	> 6000	> 6,0

* Use the relevant manufacturer's assay (test) or equivalent as it appears on the laboratory report.

** Values represent multiples of the World Health Organisation ("WHO") myocardial infarction ("MI") rule in levels and not the 99th percentile values (upper limit of normal) as quoted on the laboratory result.

Conventional Troponin Markers:

Marker	Value		
Assay (test)	Troponin Type	Unit: ng/L	Unit: ng/ml
Conventional TnT	TnT	>1000	>1,0
Conventional AccuTnl***	Tnl	>500	>0,5

*** or equivalent threshold with other Troponin I methods

Non-Troponin Markers

Marker	Value
Raised CK-MB mass	Raised 2 times or more the upper limit of normal laboratory reference range in acute presentation phase
Total CPK elevation	Raised 2 times or more the upper limit of normal laboratory reference range in acute presentation phase, with at least 6% being CK-MB

Level D: Mild heart attack of specified severity



This is defined as the death of heart muscle, due to inadequate blood supply, as evidenced by all three of the following criteria:

- 1 Compatible clinical symptoms; **AND**
- 2 Characteristic ECG changes indicative of myocardial ischaemia or myocardial infarction as per **Annexure A (a)**; **AND**
- 3 Raised cardiac biomarkers defined as any one of the following Troponin or Non-Troponin Markers:

Sensitive Troponin Markers:

Marker	Value**		
*Assay (test)	Troponin Type	Unit: ng/L	Unit: ng/ml
Roche hsTnT	TnT	> 500	> 0,5
Abbott ARCHITECT	Tnl	> 1500	> 1,5
Beckman AccuTnl	Tnl	> 2500	> 2,5
Siemens Centaur Ultra	Tnl	> 3000	> 3,0
Siemens Dimension RxL	Tnl	> 3000	> 3,0
Siemens Stratus CS	Tnl	> 3000	> 3,0

* Use the relevant manufacturer's assay (test) as it appears on the laboratory report.

** Values represent multiples of the WHO MI rule in levels and not the 99th percentile values (upper limit of normal) as quoted on the laboratory result.

Conventional Troponin Markers:

Marker	Value		
Assay (test)	Troponin Type	Unit: ng/L	Unit: ng/ml
Conventional TnT	TnT	>500	>0,5
Conventional AccuTnl***	Tnl	>250	>0,25



*** or equivalent threshold with other Troponin I methods

Non-Troponin Markers:

Marker	Value
Raised CK-MB mass	Raised above the upper limit of normal laboratory reference range, but not meeting the severity C definition (i.e. below 2 times the upper limit of normal laboratory reference range) in acute presentation phase.
Total CPK elevation	Raised above the upper limit of normal laboratory reference range, but not meeting the severity C definition (i.e. below 2 times the upper limit of normal laboratory reference range) in acute presentation phase, with at least 6% being CK-MB.

The evidence must show a definite acute myocardial infarction due to obstructive coronary heart disease. Other acute coronary syndromes, including, but not limited to, angina, are not covered by this definition.

Post coronary artery intervention Myocardial Infarction (MI)

1 LEVEL D BENEFIT REQUIRES ALL OF THE FOLLOWING:

- a) Percutaneous coronary intervention (“PCI”);
- b) Confirmed acute MI, *occurring within 24 hours post PCI;
- c) Raised Cardiac Markers as specifically set out in the table below:

Marker	Parameter
Cardiac troponin assay	As it appears in the definition of at least a heart attack of mild severity (Level D) post intervention; OR
Raised CK-MB mass reference range post intervention	Raised above the upper limit of normal laboratory reference range but below 4 times the upper limit of normal laboratory.

2 LEVEL C BENEFIT REQUIRES ALL OF THE FOLLOWING:



- a) Coronary Artery By-Pass Graft (“**CABG**”);
- b) Confirmed acute MI, *occurring within 24 hours post CABG;
- c) Raised Cardiac Markers as specifically set out in the table below:

Marker	Parameter
Cardiac troponin assay	As it appears in the definition of at least a heart attack of moderate severity (Level C) post intervention; OR
Raised CK-MB mass reference range post intervention	Raised 4 times or more the upper limit of normal laboratory reference range post intervention.



ANNEXURE A

DEFINITIONS OF ECG CHANGES

a. **ECG changes indicative of Myocardial Ischaemia that may progress to Myocardial Infarction:**

- Patients with ST-segment elevation:
 - New or presumed new ST segment elevation at the J point in two or more contiguous leads with the cut-off points greater than or equal to 0.2mV in leads V1, V2, or V3, and greater than or equal to 0.1mV in other leads;
 - Contiguity in the frontal plane is defined by the lead sequence AVL, I and II, AVF, III.
- Patients without ST-segment elevation:
 - ST-segment depression of at least 0.1 mV;
 - T-wave abnormalities only.

b. **Definition of new pathological Q-waves:**

- Any new Q-wave in leads V1 through V3;
- A Q-wave greater than or equal to 40 ms (0.04s) in leads I, II, AVL, AVF, V4, V5 or V6;
- The Q-wave changes must be present in any two contiguous leads, and be greater than or equal to 1mm in depth;
- Appearance of new complete bundle branch block.

Reference: Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction: "Myocardial Infarction Redefined – A Consensus Document"; Journal of the American College of Cardiology, Vol. 36, No 3, 2000, p959-968. Table 3 & 4, p962.



6.2. SCIDEP Definitions for non-tiered products

Any of the 4 levels of severity may be used on its own for the definition of a heart attack for non-tiered products. The final choice will be determined by price and company philosophy.

It needs to be noted that:

- Levels C and D are diagnosis-based and do not require permanent impairment. It will therefore pay a benefit even if full recovery has taken place;
- Levels A and B are impairment based and do require some degree of permanent impairment. Full recovery will not qualify for a claim under these definitions.

It is also important to note that the definitions of levels A and B are based on the basic definition of level C, with some impairment criteria added. Therefore, if either levels A or B are to be used as a standalone non-tiered benefit, the level C criteria (and ECG changes description) should be used as a starting basis, to which the criteria of either A or B are added.

7. CANCER

7.1. SCIDEP Definition for tiered products

A malignant tumour positively diagnosed with histological confirmation and characterised by the uncontrolled growth of malignant cells and invasion of tissue. The term malignant tumour includes leukaemia, lymphoma and sarcoma. The classifications are based on the latest edition of the *AJCC Cancer Staging Manual*. Pathological staging overrides the clinical staging.

For purposes of this definition, the following conditions are excluded:

- Tumours which are histologically described as benign, pre-malignant, low malignant potential. Any tumour classified as carcinoma in-situ or (Ta) by the latest edition of the *AJCC Cancer Staging Manual*;
- All tumours of the prostate unless histologically classified as having a Gleason score of 7 or more or having progressed to at least clinical *TNM classification T2NOMO*;
- All non-melanoma skin cancers are excluded. A malignant melanoma that has been histologically classified as *TINOMO* or higher is covered under this definition;



- All myelodysplastic syndromes and myeloproliferative neoplasms including, but not limited to, essential thrombocythemia, primary myelofibrosis and polycythemia vera;
- Primary cutaneous lymphoma and dermatofibrosarcoma which are confined to the skin and which have not spread to the lymph nodes or distant sites;
- All cancers only identified from tumour cells, pieces of DNA, or any other biomarkers, any of which may be present in the blood, saliva, urine, or other bodily fluids, including, but not limited to, tests known as “liquid biopsies”.

Cancers are generally classified by severity into four stages. However, brain and prostate cancer, leukaemia and lymphoma do not conform to this general classification. Therefore, additional tiering levels are provided for these cancers.

Tiering of all Cancers except prostate, leukemia, lymphoma and brain tumours

The levels are correlated to the general classification used by the *American Joint Committee for Cancer* for the type of cancer involved:

Level A – Stage 4 cancer

Level B – Stage 3 cancer

Level C – Stage 2 cancer

Level D – Stage 1 cancer

Tiering of prostate cancer

Stage 1	T1a, N0, M0, Gleason ≤ 4	Excluded
Stage 2	T1a, N0, M0, Gleason 5-6	Excluded
	T1b-c, N0, M0, Gleason 2-6	Excluded
	T1a-c, N0, M0 Gleason ≥7	Level D
	T2, N0, M0 any Gleason	Level D
Stage 3	T3, N0, M0 any Gleason	Level C



Stage 4	T4, N0, M0 any Gleason	Level B
	Any T, N1 – 3, M0 any Gleason	Level A
	Any T, any N, M1, any Gleason	Level A

Tiering of leukemia and lymphoma

Level A:

This benefit will pay for any one of the following diagnoses:

- Acute myeloid leukaemia;
- Chronic lymphocytic leukaemia, (stage III or IV on the Rai classification, Binet C, Very High risk CLL-IPI);
- Chronic myeloid leukaemia (requiring bone marrow transplant);
- Acute lymphocytic leukaemia (adults);
- Hodgkins/non hodgkins lymphoma stage IV on Ann Arbor classification system;
- Multiple myeloma stage III on the Durie-Salmon Scale.

Level B:

This benefit will pay for the following diagnoses:

- Hodgkins and non-hodgkins lymphoma stage III on Ann Arbor classification system;
- Chronic lymphocytic leukaemia (High Risk CLL IPI).

Level C

This benefit will pay for any one of the following diagnoses:

- Chronic lymphocytic leukaemia (stage I or II on the Rai classification, Binet B, intermediate risk requiring treatment CLL-IPI);
- Acute lymphocytic leukaemia (children);
- Chronic myeloid leukaemia (no bone marrow transplantation);



- Hodgkins/non-hodgkins lymphoma stage II on Ann Arbor classification system;
- Multiple myeloma stage I and II on the Durie-Salmon scale.

Level D:

This benefit will pay for any one of the following:

- Chronic lymphocytic leukaemia (stage 0, Binet A, Low Risk CLL-IPI);
- Hairy cell leukaemia;
- Hodgkins/non-hodgkins lymphoma stage 1 on Ann Arbor classification;
- Hodgkins/non-hodgkins lymphoma stage 1 on Ann Arbor classification.

Tiering of brain tumours

WHO grade II	Without neurological deficit	Severity D
WHO grade II	With neurological deficit	Severity C
WHO grade III	On diagnosis	Severity B
WHO grade IV	On diagnosis	Severity A

Grade I brain tumours will be considered under the benign brain tumour benefit should an insurer contract contain such a benefit in their critical illness product.

A table of the WHO grading for specific tumours has been included for reference purposes.

WHO Grades of CNS Tumors

Grades	I	II	III	IV
Astrocytic tumors				
Subependymal giant cell astrocytoma	X			
Pilocytic astrocytoma	X			
Pilomyxoid astrocytoma		X		



Diffuse astrocytoma		X		
Pleomorphic xanthoastrocytoma		X		
Anaplastic astrocytoma			X	
Glioblastoma				X
Giant cell glioblastoma				X
Gliosarcoma				X
Oligodendroglial tumors				
Oligodendroglioma		X		
Anaplastic oligodendroglioma			X	
Oligoastrocytic tumors				
Oligoastrocytoma		X		
Anaplastic oligoastrocytoma			X	
Ependymal tumors				
Subependymoma	X			
Myxopapillary ependymoma	X			
Ependymoma		X		
Anaplastic ependymoma			X	
Choroid plexus tumors				
Choroid plexus papilloma	X			
Atypical choroid plexus papilloma		X		
Choroid plexus carcinoma			X	
Other neuroepithelial tumors				
Angiocentric glioma	X			



Chordoid glioma of the third ventricle		X		
Neuronal and mixed neuronal-glial tumors				
Gangliocytoma	X			
Ganglioglioma	X			
Anaplastic ganglioma			X	
Desmoplastic infantile astrocytoma and ganglioglioma	X			
Dysembryoplastic neuroepithelial tumor	X			
Central neurocytoma		X		
Extraventricular neurocytoma		X		
Cerebellar liponeurocytoma		X		
Paraganglioma of the spinal cord	X			
Papillary glioneuronal tumor	X			
Rosette-forming glioneural tumor of the fourth ventricle	X			
Pineal tumors				
Pineocytoma	X			
Pineal parenchymal tumor of intermediate differentiation		X	X	
Pineoblastoma				X
Papillary tumor of the pineal region		X	X	
Embryonal tumors				
Medulloblastoma				X
CNS primitive neuroectodermal tumor				X
Atypical teratoid/rhabdoid tumor				X
Tumors of the cranial and paraspinal nerves				



Schwannoma	X			
Neurofibroma	X			
Perineurioma	X	X	X	
Malignant peripheral nerve sheath tumor		X	X	X
Meningeal tumors				
Meningioma	X			
Atypical meningioma		X		
Anaplastic/malignant meningioma			X	
Hemangiopericytoma		X		
Anaplastic hemangiopericytoma			X	
Hemangioblastoma	X			
Tumors of the sellar region				
Craniopharyngioma	X			
Granular cell tumor of the neurohypophysis	X			
Pituicytoma	X			
Spindle cell oncocytoma of the adenohypophysis	X			

Notes:

- Histological confirmation is required.
- There is no requirement to undergo current recommended treatment.
- Prophylactic mastectomy for carcinoma in situ will not qualify under this definition as the cancer is not invasive.
- The SCIDEP committee tried to avoid using classification or staging terms, but could not in the case of prostate. This was because staging definitions may change over time and are complex for the consumer.



- The SCIDEP committee decided not to exclude any HIV related cancers.

7.2. **SCIDEP definition for non-tiered products**

The cancer definitions all have two components:

- The basic definition of cancer, with the standard exclusions, as defined under the tiered product definitions;
- A severity level definition (A-D) comprising of two elements:
 - General severity levels for all cancers
 - Separate severity levels for brain and prostate cancer, leukaemia and lymphoma.

The severity levels (A-D) of all cancers, and those for brain and prostate cancer, leukaemia and lymphoma, are more or less comparable across all 4 levels.

For non-tiered definitions any severity level may be chosen, depending on pricing and product philosophy. It should be noted, however, that the definition should start with the generic definition of cancer and its standard exclusions as defined in 4.1. This needs to be followed by the definitions under the chosen severity level, including the definition for all cancers, as well as for brain and prostate cancer, leukemia and lymphoma.

The SCIDEP grid should reflect the payment per benefit appropriately.



ANNEXURE B

DETAIL ON CANCER STAGING

LYMPHOMA

Hodfkin's and non-hodgkin's lymphoma

Ann Arbor Staging System

Stage I	The lymphoma is in a lymph node or nodes in only 1 region The lymphoma is found only in 1 area of a single organ outside of the lymphatic system(E)*.
Stage II	The lymphoma is in 2 or more groups of lymph nodes on the same side of the diaphragm The lymphoma extends locally from a single group of lymph nodes into a nearby organ (IIE). It may also affect other groups of lymph nodes on the same side of the diaphragm.
Stage III	The lymphoma is found in lymph node areas on both sides of the diaphragm The lymphoma may also have extended into an area or organ next to the lymph nodes (IIIE), into the spleen (IIIS), or both (IIE,S).
Stage IV	The lymphoma has spread outside of the lymph system into an organ that is not right next to an involved node The lymphoma has spread to the bone marrow, liver, brain or spinal cord or the pleura.

*The designation "E" generally refers to extranodal contiguous extension (ie, proximal or contiguous extranodal disease).

Burkitt's lymphoma staging

A – Single solitary extra-abdominal site

AR – Intra-abdominal, more than 90% tumour resected

B – Multiple extra abdominal tumours

C – Intra abdominal tumour

D – Intra-abdominal plus one or more extra-abdominal sites



Leukaemia

CLL International Prognostic Index (CLL-IPI)

Level A (equivalent to stage IV cancer)	RAI III and IV	Binet C	Very high risk CLL IPI
Level B (equivalent to stage III cancer)			High Risk CLL IPI
Level C (equivalent to stage II cancer)	RAI I and II	Binet B	intermediate risk requiring treatment
Level D (equivalent to stage I cancer)	RAI 0	Binet A	Low risk

- If more than one criteria/staging is given, but their values do not conform to one severity level (for example Rai is level 1 which equates to SCIDEP level C, but CLL-IPI is high risk which equates to SCIDEP level B), the final severity level should be determined by giving preference to the more objective criteria, i.e. in the following order:

1. CLL-IPI
2. Binet
3. Rai

Modified Rai clinical staging system for chronic lymphocytic leukaemia

Risk	Stage	Description
Low	0	Lymphocytosis in blood or bone marrow
Intermediate	I	Lymphocytosis + enlarged lymph nodes
	II	Lymphocytosis + enlarged liver or spleen with or without lymphadenopathy
High	III	Lymphocytosis + anaemia (Hgb < 11 g/dL) with or without anaemia or enlarged liver, spleen, or lymph nodes
	IV	Lymphocytosis + thrombocytopenia (platelet count < 100,000/microL) with or without anaemia or enlarged liver, spleen, or lymph nodes



Binet Clinical staging system

Stage	Clinical features at diagnosis	Median survival (years)
A	Lymphocytosis and <3 areas of palpable lymph nodes	>7
B	Lymphocytosis and >3 areas of palpable lymph nodes	<5
C	Same as stage B with anaemia or thrombocytopenia	<2

Durie-Salmon classification

Stage	Durie-Salmon Criteria	ISS Criteria	Prognosis
I	<p>All of the following</p> <ul style="list-style-type: none"> • Hemoglobin value > 10g/dL • Serum calcium value normal or ≤ 12 mg/dL • Bone x-ray, normal bone structure (scale 0) or solitary bone plasmacytoma only • Low M – component production rate – IgG value <5 g/dL; IgA value <3 g/dL <p>Bence Jones protein <4 g/24 h</p>	β ₂ -M < 3.5 mg/dL and albumin ≥3.5 g/dL	60 months Median Survival
II *	Neither stage I or III	Neither stage I nor stage III	41 months
III	<p>On or more of the following:</p> <ul style="list-style-type: none"> • Haemoglobin value <8.5 g/dL • Serum calcium vaue >12 mg/dL • Advanced lytic bone lesions (scale 3) - High M-component production 	β ₂ –M ≥ 5.5 mg/dL	23 months



	rate IgG value >7 g/dL; IgA value >5 g/dL – Bence Jones Protein >12g/24 h		
--	---	--	--

Durie-Samon sub classification (either A or B)

A: Relatively normal renal function (serum creatinine value <2.0 mg/dL (<177 µmol/l))

B: Abnormal renal function (serum creatinine value ≥ 2.0 mg/dL (> 177 µmol/l)) – Stage B worse outcome

* Stage II = β₂-M <3.5 or β₂-M 3.5 – 55 mg/dL, and albumin <3.5 g/dL

Stage	Clinical features at diagnosis	Median survival (years)
A	Lymphocytosis and <3 areas of palpable lymph nodes	>7
B	Lymphocytosis and >3 areas of palpable lymph nodes	<5
C	Same as stage B with anaemia or thrombocytopenia	<2



DOCUMENT HISTORY

Date	Publication / Amendments
1 September 2009	First version of the Standard
1 January 2011	Version 2- Addition of Non-tiered definitions.
1 June 2012	Version 3-Changes of semantic nature. Instructions on how the tiered definitions should be adapted for use in a stand-alone format for a non-tiered product was included.
1 January 2015	Version 4 -Changes to introduction and definitions- almost entirely of a technical and cosmetic nature
1 July 2022	Version 5- review of the definitions and various changes made. Layman definitions removed.
19 March 2025	Wording changes made arising from Competition law review

RESPONSIBLE COMMITTEES AND SENIOR POLICY ADVISOR

Responsible Board Committee	ASISA Life and Risk Board Committee
Responsible Standing Committee	Medical and Underwriting Standing Committee
Responsible SPA	ASISA Point Person to the Life and Risk Board Committee